ProKidney Corp. (BMV:PROK)

Market Cap	4.90B +81.7%
Revenue (ttm)	16.08M +1,075.0%
Net Income	-1.24B
EPS	-9.27
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	29,875
Average Volume	7,589
Open	34.50
Previous Close	36.90
Day's Range	34.00 - 35.83
52-Week Range	12.18 - 132.00
Beta	n/a
RSI	40.07
Earnings Date	Mar 24, 2026

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, a...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 204
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: PROK

Financial Performance

In 2025, ProKidney's revenue was $893,000, an increase of 1075.00% compared to the previous year's $76,000. Losses were -$68.99 million, 12.7% more than in 2024.

Financial numbers in USD